Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. Class A

Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. Class A

SSZSE:300937
19.76
CNY
-0.47
(-2.32%)
-0.47EPS
2.30BMarket Cap
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
21.9
25.26
29.34
31.86
38.74
37.19
41.9
46.09
45.94
46.57
47.65
Basic EPS, GAAP
0.51
0.71
0.82
0.9
0.75
0.07
0.43
0.57
0.16
-0.12
-0.28
Free Cash Flow per Basic Share
-0.25
0.15
-0.54
0.08
0.47
-2.03
1.42
-1.57
0.96
-0.22
- -
Dividend per Share
- -
- -
0.12
0.03
0.18
0.23
0.06
0.25
0.32
0.19
0.09
Book Value per Share
3.21
4.47
5.73
6.63
7.22
8.09
8.48
8.85
8.79
8.57
8.22
Tangible Book Value per Share
3.21
3.96
5.28
6.15
6.63
7.62
7.68
7.95
7.91
7.87
7.59
Basic Weighted Avg Shares
57
63
69
72
72
91
95
96
96
96
93
Sales/Revenue/Turnover
1,241
1,587
2,024
2,289
2,790
3,401
3,969
4,430
4,395
4,454
4,423
Operating Margin (%)
3.18
3.56
3.69
3.6
2.51
0.31
2.01
2.18
0.99
1
0.1
Depreciation Expense
1
2
4
8
10
17
24
24
32
28
- -
Net Income, GAAP
29
45
57
65
54
6
41
55
15
-11
-26
Effective Tax Rate (%)
19.63
17.49
16.87
16.75
15.22
17.17
20.33
20.15
9.77
273.55
- -
Profit Margin (%)
2.33
2.81
2.79
2.82
1.94
0.19
1.03
1.24
0.34
-0.25
-0.59
Working Capital
170
189
255
302
309
454
510
574
538
503
468
LT Debt
- -
- -
- -
- -
3
6
3
5
10
4
5
Total Equity
182
292
413
487
525
788
817
849
837
800
764
Return on Invested Capital (%)
- -
18.79
15.17
12.78
9.48
1.03
3.71
4.6
0.97
-1.57
- -
Return on Capital (%)
- -
18.82
16.32
14.76
10.42
1.02
5.23
5.59
2.8
-3.27
- -
Return on Common Equity (%)
- -
18.82
16.09
14.58
10.87
0.99
5.14
6.61
1.76
-1.35
-3.24

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
343
295
351
LT Borrowings
- -
- -
- -
LT Finance Leases
3
4
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
96
96
96
Market Capitalization
2,815
1,845
2,301

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,562
1,610
1,834
Cash, Cash Equivalents & STI
445
516
694
Accounts Receivable, Net
382
413
414
Inventories
488
465
477
Total Current Liabilities
1,071
1,118
1,367
Payables & Accruals
- -
- -
- -
ST Debt
343
295
351
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
10.37%
-4.41%
Free Cash Flow
- -
-262.62%
-122.59%
Net Income, GAAP
- -
46.96%
-175.15%
Sales/Revenue/Turnover
- -
10.15%
1.35%
Total Cash Common Dividend
- -
65.58%
-41.29%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,237
988
1,010
1,159
4,395
2025
1,138
1,020
- -
1,212
4,454
2026
1,114
1,067
1,030
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.1
0.03
0.02
0.01
0.16
2025
0.04
-0.12
- -
-0.03
-0.12
2026
-0.03
-0.08
-0.13
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.25
0.02
0.02
0.32
2025
0.02
0.12
- -
0.04
0.19
2026
0.02
0.01
0.03
- -
- -

Company Description

CEO
Shun jun Chen
Full Time Employees
1,045
Sector
Technology services
Industry
Internet software/Services
Address
Chengdu China
IPO Date
Jan 27, 2021
Business
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. is a China-based pharmaceutical supply chain and digital healthcare enterprise specializing in pharmaceutical wholesale, B2B e-commerce distribution, modern third-party logistics, and retail pharmacy empowerment services. Founded in 2007 and headquartered in Chengdu, Sichuan Province, the company primarily serves community retail pharmacies, primary healthcare clinics, village and township medical institutions, and commercial pharmaceutical distributors across Southwest China and select nationwide markets. The company operates across integrated business segments encompassing Pharmaceutical Commercial Distribution, B2B E-Commerce Platform Operations, Retail Chain Pharmacy Management, and Modern Health Logistics. Its comprehensive product and service offerings comprise chemical pharmaceutical preparations; proprietary Chinese medicines; biochemical products and biological agents; traditional Chinese medicine (TCM) decoction pieces and herbal preparations; medical devices, diagnostic instruments, and surgical consumables; nutritional supplements and functional health foods; personal protective equipment and dermocosmetics; the proprietary Yaoyigou B2B online pharmaceutical procurement platform; cloud-based SaaS store management and inventory management systems for retail pharmacies; temperature-controlled cold-chain warehousing and pharmaceutical logistics services; and omni-channel franchise empowerment solutions for member retail pharmacies. In recent developments, the company has advanced its strategic transformation into an AI-enabled and data-driven healthcare ecosystem platform. Over the past two years, Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. has established strategic cooperation agreements with prominent upstream pharmaceutical manufacturers to expand its direct-source brand distribution and proprietary product lines. The company has expanded its regional logistics and fulfillment network through investments in automated warehousing and cold-chain infrastructure, while scaling its smart pharmacy solutions with the deployment of automated 24-hour smart medicine cabinets and integrated online-to-offline instant delivery fulfillment. Additionally, the company has expanded its digital service capabilities by launching specialized marketing SaaS tools, entering strategic partnerships in traditional Chinese medicine clinic operations, and deepening its supply chain finance and digital operational support for grassroots medical providers across western China.